Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

SUMO1 modulates Aβ generation via BACE1 accumulation.

Yun SM, Cho SJ, Song JC, Song SY, Jo SA, Jo C, Yoon K, Tanzi RE, Choi EJ, Koh YH.

Neurobiol Aging. 2013 Mar;34(3):650-62. doi: 10.1016/j.neurobiolaging.2012.08.005. Epub 2012 Sep 11.

PMID:
22975420
2.

Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.

Natunen T, Takalo M, Kemppainen S, Leskelä S, Marttinen M, Kurkinen KMA, Pursiheimo JP, Sarajärvi T, Viswanathan J, Gabbouj S, Solje E, Tahvanainen E, Pirttimäki T, Kurki M, Paananen J, Rauramaa T, Miettinen P, Mäkinen P, Leinonen V, Soininen H, Airenne K, Tanzi RE, Tanila H, Haapasalo A, Hiltunen M.

Neurobiol Dis. 2016 Jan;85:187-205. doi: 10.1016/j.nbd.2015.11.005. Epub 2015 Nov 10.

PMID:
26563932
3.

NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42.

Buggia-Prevot V, Sevalle J, Rossner S, Checler F.

J Biol Chem. 2008 Apr 11;283(15):10037-47. doi: 10.1074/jbc.M706579200. Epub 2008 Feb 8.

4.

Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.

McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S.

J Biol Chem. 2007 Sep 7;282(36):26326-34. Epub 2007 Jul 6.

5.

AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.

Eketjäll S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, Radesäter AC, Eliason K, Briem S, Appelkvist P, Niva C, Berg AL, Karlström S, Swahn BM, Fälting J.

J Neurosci. 2013 Jun 12;33(24):10075-84. doi: 10.1523/JNEUROSCI.1165-13.2013.

6.

In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.

Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, Tyler KX, Kahana J, Ellis J, Jin L, Steele T, Stachel S, Coburn C, Simon AJ.

J Pharmacol Exp Ther. 2008 Mar;324(3):957-69. Epub 2007 Dec 21.

7.

Reduction of β-amyloid accumulation by reticulon 3 in transgenic mice.

Araki W, Oda A, Motoki K, Hattori K, Itoh M, Yuasa S, Konishi Y, Shin RW, Tamaoka A, Ogino K.

Curr Alzheimer Res. 2013 Feb;10(2):135-42.

PMID:
22742855
8.

Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice.

Arbel-Ornath M, Becker M, Rabinovich-Toidman P, Gartner M, Solomon B.

J Alzheimers Dis. 2010;22(2):469-82. doi: 10.3233/JAD-2010-100753.

PMID:
20847413
9.

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE.

J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011.

10.

RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model.

Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, Mook-Jung I.

FASEB J. 2009 Aug;23(8):2639-49. doi: 10.1096/fj.08-126383. Epub 2009 Mar 30.

PMID:
19332646
11.

Thiamine deficiency increases β-secretase activity and accumulation of β-amyloid peptides.

Zhang Q, Yang G, Li W, Fan Z, Sun A, Luo J, Ke ZJ.

Neurobiol Aging. 2011 Jan;32(1):42-53. doi: 10.1016/j.neurobiolaging.2009.01.005. Epub 2009 Feb 23.

PMID:
19233513
12.

PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein.

Xie J, Guo Q.

J Biol Chem. 2005 Apr 8;280(14):13824-32. Epub 2005 Jan 25.

13.

Presenilin 1 is involved in the maturation of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1).

Kuzuya A, Uemura K, Kitagawa N, Aoyagi N, Kihara T, Ninomiya H, Ishiura S, Takahashi R, Shimohama S.

J Neurosci Res. 2007 Jan;85(1):153-65.

PMID:
17075903
14.

The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

Vassar R.

J Mol Neurosci. 2001 Oct;17(2):157-70. Review.

PMID:
11816789
15.

Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.

Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB.

J Neurochem. 2007 Feb;100(3):802-9.

16.

Novel mutations introduced at the beta-site of amyloid beta protein precursor enhance the production of amyloid beta peptide by BACE1 in vitro and in cells.

Shi XP, Tugusheva K, Bruce JE, Lucka A, Chen-Dodson E, Hu B, Wu GX, Price E, Register RB, Lineberger J, Miller R, Tang MJ, Espeseth A, Kahana J, Wolfe A, Crouthamel MC, Sankaranarayanan S, Simon A, Chen L, Lai MT, Pietrak B, DiMuzio J, Li Y, Xu M, Huang Q, Garsky V, Sardana MK, Hazuda DJ.

J Alzheimers Dis. 2005 Apr;7(2):139-48; discussion 173-80.

PMID:
15851852
17.

BACE1: the beta-secretase enzyme in Alzheimer's disease.

Vassar R.

J Mol Neurosci. 2004;23(1-2):105-14. Review.

PMID:
15126696
18.

BACE1 structure and function in health and Alzheimer's disease.

Cole SL, Vassar R.

Curr Alzheimer Res. 2008 Apr;5(2):100-20. Review.

PMID:
18393796
19.

Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.

Georgievska B, Gustavsson S, Lundkvist J, Neelissen J, Eketjäll S, Ramberg V, Bueters T, Agerman K, Juréus A, Svensson S, Berg S, Fälting J, Lendahl U.

J Neurochem. 2015 Feb;132(4):477-86. doi: 10.1111/jnc.12937. Epub 2014 Sep 18.

20.

Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.

Chiocco MJ, Kulnane LS, Younkin L, Younkin S, Evin G, Lamb BT.

J Biol Chem. 2004 Dec 10;279(50):52535-42. Epub 2004 Sep 27.

Supplemental Content

Support Center